<figure><img alt="J&J Submits EUA for Single-Shot Janssen COVID Vax Candidate" src="https://dev.rodpub.com/images/227/517_main.jpg"></img></figure>
<a href="https://www.contractpharma.com/heaps/view/7447/2/342369">Johnson &amp; Johnson&rsquo;s</a> <a href="https://www.janssen.com">Janssen Biotech, Inc.</a>, submitted an application to the U.S. FDA requesting Emergency Use Authorization for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on efficacy and safety data from the Phase 3 ENSEMBLE trial demonstrating the investigational single-dose vaccine met all primary and key secondary endpoints. The company expects to have product available to ship immediately following authorization.
The Phase 3 ENSEMBLE study was designed to evaluate the safety and efficacy of the investigational vaccine in protecting against both moderate and severe COVID-19 disease, with assessment of efficacy as of day 14 and as of day 28 as co-primary endpoints.
Among all participants from different geographies and including those infected with an emerging viral variant, Janssen&rsquo;s COVID-19 vaccine candidate was 66% effective overall in preventing moderate to severe COVID-19, 28 days after vaccination. The onset of protection was observed as early as day 14. The level of protection against moderate to severe COVID-19 infection was 72% in the U.S., 66% in Latin America, and 57% in South Africa, 28 days post-vaccination.
The investigational vaccine leverages the company's AdVac vaccine platform, which was also used to develop and manufacture Janssen's European Commission-approved Ebola vaccine and construct its investigational Zika, RSV, and HIV vaccines. The safety profile observed was consistent with other investigational vaccines using Janssen's AdVac technology among more than 200,000 people to date.
Manufacturing and Supply Chain 
 The Janssen investigational vaccine is compatible with standard vaccine distribution channels. If authorized, the single-dose vaccine is estimated to remain stable for two years at -4&deg;F (-20&deg;C), at least three months of which can be stored in most standard refrigerators at temperatures of 36&deg;F&ndash;46&deg;F (2&deg;-8&deg;C). The company will ship the vaccine using the same cold chain technologies it uses to transport other medicines.
R&amp;D for the investigational Janssen COVID-19 vaccine including the ENSEMBLE trial and the delivery of doses for the U.S. has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA), and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).

Food and Drug Administration

United States of America

COVID-19

vaccine

Janssen Pharmaceutica

South Africa

HIV/AIDS

National Institute of Allergy and Infectious Diseases

Latin America

single

Janssen Biotech

Johnson & Johnson’s Janssen Biotech, Inc., submitted an application to the U.S. FDA requesting Emergency Use Authorization for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on efficacy and safety data from the Phase 3 ENSEMBLE trial demonstrating the investigational single-dose vaccine met all primary a

J&J Submits EUA for Single-Shot Janssen COVID Vax Candidate

Wednesday, August 13, 2025, 1:00 PM - 1:30 PM (UTC-04:00) Eastern Time (US & Canada)
Join us for an in-depth conversation with Ullrich Mayeski, J.D., Director of Community Engagement, Healthcare, GS1 US. We will explore how technologies like 2D barcodes are transforming supply chain visibility and transparency—especially in the pharmaceutical space

Beyond Compliance: Enhancing Supply Chain Transparency with New Technologies

FDA deadline update
Consider me surprised. I figured if a delay was coming, it would have already happened. How are we understanding this? Only delays in mitigation and control are allowed or any delay, with justification?
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits#tim

Excipient Nitrosamine Risk Assessment Tool

Hikma Pharmaceuticals USA announced on June 28, 2025 that it is investing $1 billion by 2030 to expand its generic-drug R&D and manufacturing capabilities in its Ohio and New Jersey, United States, facilities. The company has invested $4 billion in the past 15 years to expand its US operations, which began in 1991, and now has an annual domestic ca

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

On June 26, 2025, FDA announced the elimination of Risk Evaluation and Mitigation Strategies (REMS) for seven approved B-cell maturation antigen (BCMA)- and CD19-directed autologous chimeric antigen receptor (CAR)-T cell therapies (1). The agency determined that REMS is no longer required to ensure that the benefits of these therapies outweigh thei

Biopharm Industry Impacts of FDA Eliminating REMS for CAR-T Therapies

Veranova has appointed Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides.
Villain brings extensive expertise in peptide and oligonucleotide development and manufacturing to Veranova as the company continues to strengthen its position as a key player in the Peptide and Oligonucleotide (TIDES) space.
“Dr. Villain, and his holistic

Veranova Appoints Dr. Matteo Villain as VP of Peptides & Oligonucleotides

BD Webinar, June 26, 2025
Key Takeaways:
· While self-injection is growing for many types of biologics, there are challenges surrounding this delivery method.
· The 8mm needle and thinner wall technology of the Neopak™ XtraFlow™ syringe help lower patient anxiety and discomfort.
· There is a reduced injection force with the new syringe, so patients

Improving Self-Injection Delivery of Biologics Through Better Needle Choices

Monday, June 30, 2025
Innovent Biologics, Inc.a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China’s National Medical Products Administration (NMPA) has appr

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management

Advent of a new era of collaboration
2 July 2025, Brussels Hybrid conference
Speakers’ Bios
Olivér VÁRHELYI COMMISSIONER
Sandra GALLINA
Olivér Várhelyi is a Hungarian lawyer and diplomat who has served as European Commissioner for Health and Animal Welfare since December 1, 2024, in the second von der Leyen Commission. His mandate focuses on advanc

EU health technology assessment:

If you are having difficulty obtaining a medicine that has been prescribed to you, talk to your doctor or pharmacist to discuss suitable options to continue your care.
More information about medicine shortages and how to access alternative medicines is available at the Medicine Shortages hub
BELKYRA deoxycholic acid 10 mg/mL injection glass vial
AU

deoxycholic acid - medicine shortage information

During Brazil President Luiz Inácio Lula da Silva's mission to France, the research institute Fiocruz, which was part of the official Presidential entourage, signed a new alliance with the Institut Pasteur and French pharma major Sanofi (Euronext: SAN) to promote innovative solutions and advances in vaccine technology.
The agreement that Fiocruz si

Fiocruz, Institut Pasteur and Sanofi sign vaccine alliance

Hikma Pharmaceuticals will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment will further expand Hikma’s domestic capabilities to develop, produce and deliver a broad range of medicines.
Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years

Hikma Pharmaceuticals to Invest $1B in U.S. Manufacturing & R&D Capabilities

Vetter celebrated the start of construction on its new clinical manufacturing site in the Chicago area with an official groundbreaking ceremony. The state-of-the-art facility, which is being built in Des Plaines, Illinois, is expected to be ready for media fill by the end of 2029. This $285 million investment will strengthen Vetter’s position as a

Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony

The HERA Info Days aim to present the main strands of work of the European Commission’s Health Emergency Preparedness and Response Authority, showcase its success stories, and pinpoint funding opportunities in the field.
By participating in HERA’s Info Day in Nicosia, you will get the chance to interact with HERA, learn more about funding schemes o

Health Emergency Preparedness and Response Authority: Connecting stakeholders for a safer future

Monday, June 30, 2025
Sobi® has announced that the US Food and Drug Administration (FDA) has approved Gamifant® (emapalumab-lzsg) as the first treatment for adults and children, including newborns, with macrophage activation syndrome (MAS) associated with Still’s disease.
MAS is a severe, potentially life-threatening complication seen in Still’s di

Sobi Receives Approval for Gamifant® as Treatment for Macrophage Activation Syndrome in Still's Disease

By Barbara Obstoj-Cardwell. Editor
US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide reduced weight by 20%. In deal-making news last week, US drugmaker Amarin struck a deal with Italy’s Recordati for the marketing of its cardiovascular drug Vazkepa in 59 countries, mostly Europe

The week in pharma: action, reaction and insight – week to June 27

July 15, 2025, Institut Pasteur du Maroc, Casablanca
Single-use technologies offer a streamlined and flexible approach to biopharmaceutical manufacturing. But to find the right solutions for your process, it’s critical to consider factors like compliance, sustainability, and efficiency — all of which can have a large impact on design, cost, and fea

Sartorius at Institut Pasteur, Casablanca

(20 µg/ml salmon gonadotropin releasing hormone analog + 10 mg/ml domperidone) Injectable Solution Spawning aid for intraperitoneal or intramuscular injection FOR USE IN FINFISH BROODSTOCK ONLY
LEGAL STATUS -- In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the

(20 µg/ml salmon gonadotropin releasing hormone analog + 10 mg/ml domperidone)

1.375 in
User Safety Warnings: Before use, read package insert for complete product information Not for use in humans. Keep out of the reach of children. May damage fertility. Pregnant women should exercise caution because exposure may damage the unborn child. Use in a well-ventilated area. Wear gloves, goggles, and suitable protective clothing. Ca

CAUTION: FOR USE IN FINFISH BROODSTOCK ONLY.

Aenova, a contract development and manufacturing organization, announced on June 27, 2025 that it is expanding its sterile manufacturing facility in Latina, Italy with a new cold chain warehouse that will be connected to the existing facility. The new warehouse will support a wide range of cold chain products without the need for special adaptation

Aenova Adds Cold Chain Warehouse to Latina, Italy Site

Pharmaceutical Technology® Group was able to interview more than a half dozen executives in the biopharmaceutical industry as part of its coverage of the Biotechnology Innovation Association (BIO) International Convention, which took place in Boston June 16–19, 2025.
The conference was bookended by major developments with impacts to healthcare with

At BIO 2025, As Political Shifts Continue, Key Leaders Respond

Mark Foster, General Manager of Oliver Design, shares insights on balancing patient needs, manufacturability, and sustainability in biopharma packaging.
Pharmaceutical packaging is no longer just about containment and compliance—it’s about enabling patients, streamlining manufacturing, and accelerating time to market. In this Q&A, Mark Foster, Gene

Design with Purpose: How Oliver Design is Shaping the Future of Pharma Packaging

Salvador Alvarado, Senior Product Manager at Thermo Fisher Scientific shares the DynaDrive single-use bioreactor, which offers scalability from one liter to five thousand liters. Its square design maximizes efficiency in mixing and ensures optimal performance, aligning with leading family vessels. The bioreactor features both microsparger and macro

Now available: 5L Thermo Fisher Scientific DynaDrive Single-Use Bioreactor

Vetter continues to expand in the US, breaking ground on a clinical production facility in Des Plaines.
Vetter celebrated the start of construction on its new clinical manufacturing site in the Chicago area with an official groundbreaking ceremony. The state-of-the-art facility, which is being built in Des Plaines, Illinois, is expected to be ready

CDMO Vetter Pharma Breaks Ground On New Clinical Manufacturing Aseptic Filling Facility In Illinois

Nitrosamines Exchange A knowledge based community for all-things Nitrosamine
Topics
Upcoming Events
Knowledge Base
LATAM Reguladores
Analytical Hub
CAC&TR Regulators
Events / Workshops / Webinars
N-nitrosamines Chemistry
Limits of Nitrosamines
Root Causes
Confirmatory Testing & Analytical Challenges
Nitrosamines in the News
New Scientific Knowledge

Calling our Risk Assessment Experts

Friday, June 27, 2025
Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, today announced a strategic collaboration with AiCella, a company focused on harnessing the power of artificial intelligence (AI) to optimize the development of cell therapy productio

Invetech and AiCella Announce Strategic Collaboration to Advance Cell Therapy Innovation

Advertise in the PDA News uPDAte & Buyer’s Guide

Contact

Advertise

Other industries

Lessons from a cross-functional roundtable at PDA Week 2025
Peter Makowenskyj, MEng, G-CON Manufacturing and Toni Manzano, PhD, Aizon
The pharmaceutical industry stands at a pivotal moment as advanced digital technologies, particularly artificial intelligence (AI), are increasingly integrated into manufacturing environments.
During PDA Week 2025, a